All In Biotech

Drug Trial Radar · NCT06704581

A Study of BGM0504 Injection in Participants With Obesity or Overweight

A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of BGM0504 Injection in Chinese Non-diabetes Participants With Overweight or Obese

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 652 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

652

Actual

Start

Oct 29, 2024

Primary completion

Mar 17, 2026

Study completion Mar 17, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an adjunct to diet, exercise, and behavioral interventions in overweight or obese non-diabetic adults in China for weight management, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.

Conditions

  • Overweight or Obesity

Interventions

  • 5 mg BGM0504 injectionDrug

    5mg BGM0504 injection administered subcutaneously (SC) once a week.

  • 10 mg BGM0504 injection administered subcutaneously (SC) once a weekDrug

    10mg BGM0504 injection administered subcutaneously (SC) once a week.

  • 15 mg BGM0504 injectionDrug

    15mg BGM0504 injection administered subcutaneously (SC) once a week.

  • BGM0504 placeboDrug

    BGM0504 placebo administered SC once a week.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Body WeightTime frame: Baseline,Week 36
  2. Percentage of Participants Who Achieve≥5% Body Weight ReductionTime frame: Baseline,Week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.